PI3K/p110β-specific inhibitors in castration-resistant prostate cancer.
- Author:
Ben-Yi LI
1
;
Jian-Hong WU
2
Author Information
1. Department of Urology， The University of Kansas Medical Center， Kansas City， Ks 66160.
2. School of Medicine, Shaoxing College of Arts and Sciences, Shaoxing, Zhejiang 312000, China.
- Publication Type:Journal Article
- Keywords:
advanced prostate cancer;
castration-resistance;
p110-specific inhibitors;
targeted therapy
- MeSH:
Aniline Compounds;
therapeutic use;
Chromones;
therapeutic use;
Humans;
Imidazoles;
therapeutic use;
Male;
Morpholines;
therapeutic use;
Neoplasm Proteins;
antagonists & inhibitors;
Phosphatidylinositol 3-Kinases;
metabolism;
Phosphoinositide-3 Kinase Inhibitors;
Prostatic Neoplasms, Castration-Resistant;
drug therapy;
enzymology;
Protein Kinase Inhibitors;
therapeutic use
- From:
National Journal of Andrology
2017;23(3):195-199
- CountryChina
- Language:Chinese
-
Abstract:
Advanced prostate cancer, especially at the castration-resistant stage, remains incurable clinically and, therefore, urgently requires new therapeutics for the patients. PI3K is a family of critical cell signal transduction molecules and their over-activation is an important factor in cancer development and progression. It has been demonstrated that class IA PI3K p110 is drastically overexpressed in prostate cancer and involved in androgen receptor-mediated gene expression and castration-resistant progression and regarded as a potential therapeutic target for prostate cancer. Several p110-specific inhibitors have been reported recently and two of them, GSK2636771 and AZD8186, are being tested in clinical trials.
